REG - EDX Medical Group - First Day of Dealings on AIM
Wed 07:15
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260513:nRSM0473Ea&default-theme=true
RNS Number : 0473E EDX Medical Group PLC 13 May 2026
13 May 2026
EDX Medical Group PLC
("EDX Medical" or the "Company")
First Day of Dealings on AIM
CAMBRIDGE, UK: EDX Medical (TIDM: EDX), which develops innovative digital
diagnostic products and services supporting personalised treatments for cancer
and infectious diseases, is pleased to announce that the admission of its
ordinary shares of £0.01 each ("Ordinary Shares") to trading on the AIM
Market ("AIM"), a market operated by the London Stock Exchange, will take
place today ("Admission"). Dealings in the Ordinary Shares on AIM will
commence at 8:00 a.m. today under the TIDM "EDX" and ISIN: GB00BNDMJS47.
Additionally, the Company's Ordinary Shares will be withdrawn from trading on
the Apex Segment of the Aquis Stock Exchange Growth Market with effect from
8:00 a.m. today, in accordance with AQSE Rule 5.3.
Key Investment Highlights
· Commercially scalable clear growth strategy, with potential to
compete successfully in the £10 billion+ clinical diagnostics market in UK
and Europe.
· Specialist business model based on proprietary products addressing
major areas of significant global impact on health, particularly cancer and
infectious diseases.
· Building a portfolio of unique, 'best in class', validated
diagnostic products and services for the identification of genetic risk, early
disease detection and characterisation.
· Early revenues and market access via exclusive distribution
partnerships with Caris Life Sciences and with Curesponse Ltd.
· Strong product pipeline via collaboration with Thermo Fisher
based on in-licensed intellectual property from Oxford and Cambridge
Universities and others.
· Pioneering multiplex 'point of care' test platform, providing
quantitative data on multiple biomarkers, with digital reporting via mobile
device, for sepsis and prostate cancers in development.
About EDX Medical
EDX Medical develops, validates and commercialises innovative digital
diagnostic products and services, generating valuable biological insights that
enable cost effective and timely delivery of personalised treatment for
cancer, heart disease and infectious diseases.
By translating clinical insights into pragmatic solutions combining advanced
biological and digital technologies, EDX Medical seeks to improve cost
effectively the detection and characterisation of disease. The Directors
believe that early disease detection and biologically-based personal treatment
is the most impactful way of improving patient outcomes and survival whilst
lowering the cost of healthcare globally. EDX focusses on two areas of
greatest global health and economic impact - cancer and infectious diseases.
EDX Medical provides healthcare professionals, providers, payors and patients
with access to a portfolio of clinical diagnostic products and services that
the Directors believe represent leading technologies. The Company operates a
molecular biology and diagnostics laboratory in Cambridge, UK, providing
testing services accredited to ISO 15189(2022) by the United Kingdom
Accreditation Service (UKAS) and has strategic product and technology
partnerships with organisations such as Thermo Fisher EMEA Ltd, a recognised
world leader in supplying life sciences solutions.
In order to compete successfully in the clinical diagnostics sector, EDX
Medical has established core competencies in the identification, development
and validation of tests and associated secure data analytics and reporting to
meet the latest in-vitro diagnostics regulatory standards in the UK and
Europe. The Board believes that these skills and technical expertise, combined
with marketing and distribution capabilities make EDX Medical a strong partner
for collaborators.
EDX Medical provides both 'laboratory assays' and 'point of care' testing -
two major segments of the growing global clinical diagnostics market. Both
product lines are considered to be capable of addressing large global public
and private sector markets for improved healthcare testing.
The laboratory assay portfolio includes market-ready advanced cancer tests
from world-leading partners under exclusive distribution arrangements
contributing initial revenues, alongside a growing number of products
developed by EDX Medical in partnership with strategic partners including
Thermo Fisher EMEA. EDX Medical is initially providing these assay services
from its own laboratory while conducting product validation in the UK. It is
intended that the optimised assays will then be made into product kits which
will be validated and submitted for CE-IVDR regulatory approval, for sale to
laboratories in the public and private healthcare sector across Europe. The
Directors believe this is an attractive and highly scalable business model.
The 'point of care' (PoC) test range is based on a patent-pending multiplex
test platform which provides highly sensitive and quantitative data for
multiple key biomarkers from a handheld 20-minute test device. Secure data
analytics and reporting is delivered to a designated mobile device. Initial
applications currently in development include PoC tests for sepsis and
prostate cancer.
Professor Sir Chris Evans, OBE, founder and chief scientific officer of EDX
Medical, commented: "We have a vision to build a company that develops and
brings to market only the very best diagnostic tests that are game changing
and life-saving for people. I'm delighted we have made really strong progress
so far. Our admission to AIM is a clear reflection of how far we have come,
staying true to our vision. We have enjoyed tremendous ongoing support from
our investors and believe that moving to AIM will create further opportunities
for investors in the company."
For enquiries, please contact:
EDX Medical Group plc
Dr Mike Hudson (Chief Executive Officer) +44 (0)7812 345 301
Canaccord Genuity Limited (Nominated Adviser and Broker)
Stuart Andrews +44 (0) 20 7523 8318
Media House International
Ramsay Smith +44 (0)7788 414856
ramsay@mediahouse.co.uk (mailto:ramsay@mediahouse.co.uk)
Gary McQueen + 44 (0)7834 694609
gary@mediahouse.co.uk (mailto:gary@mediahouse.co.uk)
IFC Advisory (Investor Relations)
Graham Herring +44 (0) 203 934 6630
Tim Metcalfe
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ADMQLLFFQELFBBE
Copyright 2019 Regulatory News Service, all rights reserved